📖Complete GuideUpdated 2026🔬Evidence-Based

Ecnoglutide Guide

XANO Pharmaceuticals

Complete guide to Ecnoglutide. Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In ..

Top dose (24 wks)
~16%
Safety
Manageable
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
ACTIVE MEDICATIONS
EcnoglutideB12
ECNOGLUTIDE
🔥 14
2
days away
Thursday · 7.5mg
Medication Supply
Ecnoglutide
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
EcnoglutideRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
ACTIVE MEDICATIONS
EcnoglutideB12
ECNOGLUTIDE
🔥 14
2
days away
Thursday · 7.5mg
Medication Supply
Ecnoglutide
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
EcnoglutideRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01BACKGROUND

XANO Pharmaceuticals\' GLP-1 Receptor Agonist

Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In Phase 2 trials, it demonstrated up to approximately 16% weight loss over 24 weeks in adults with obesity. Its development adds to the growing global pipeline of GLP-1 therapies aiming to provide more accessible treatment options. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.

02DEEP DIVE

What Is Ecnoglutide?

Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In Phase 2 trials, it demonstrated up to approximately 16% weight loss over 24 weeks in adults with obesity. Its development adds to the growing global pipeline of GLP-1 therapies aiming to provide more accessible treatment options.

Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.

03WHAT TO TRACK

How It Works

01
🔬
GLP-1 Targeting
Potent GLP-1 receptor activation. Sustained appetite suppression. Once-weekly injection. Track doses in Shotlee
02
🎯
Metabolic Effects
Improved glucose control. Insulin sensitivity benefits. Cardiometabolic improvements. Log labs in Shotlee
03
📊
Clinical Promise
Competitive weight loss results. 16% in 24 weeks (Phase 2). Global development pipeline. Monitor progress in Shotlee
04
🔬
Why This Matters
Ecnoglutide\'s Phase 2 results showing 16% weight loss in just 24 weeks are competitive with established GLP-1s. More options in the GLP-1 class mean more choices for patients and potentially better p
04KEY NUMBERS

Clinical Data

📈
Top dose (24 wks)
0%
💪
Safety
0Manageable
05MECHANICS

Side Effects

1
Nausea (dose-dependent)
2
GI discomfort
3
Decreased appetite
4
Track symptoms in Shotlee
06WHAT TO TRACK

Vital Protocol FAQs

01
🔬
What is Ecnoglutide?
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist showing approximately 16% weight loss in 24-week Phase 2 trials. Track your GLP-1 protocol in the Shotlee app.
02
🧬
How does it compare to Semaglutide?
Both are GLP-1 agonists. Ecnoglutide\'s 16% loss in 24 weeks is competitive, but head-to-head data is needed. Use Shotlee to compare your own results across medications.
07FAQ

Guide FAQs

Complete guide to Ecnoglutide. Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In ..

Yes. Shotlee supports tracking Ecnoglutide doses, side effects, and health metrics. It is free to use.

Free · Always

Track Your Ecnoglutide Protocol in Shotlee

Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.

📚References & sources

Start tracking